Italia markets closed

SWTX Jan 2025 40.000 call

OPR - OPR Prezzo differito. Valuta in USD.
Aggiungi a watchlist
6,700,00 (0,00%)
Alla chiusura: 10:07AM EDT
Schermo intero
Chiusura precedente6,70
ApertoN/D
Denaro4,60
Domanda8,90
Prezzo d'esercizio40,00
Scadenza2025-01-17
Min-Max giorno6,70 - 6,70
Contratto - Min-MaxN/D
VolumeN/D
Open Interest5
  • GlobeNewswire

    SpringWorks Therapeutics Reports Second Quarter 2023 Financial Results and Recent Business Highlights

    – Presented additional Phase 3 DeFi data at ASCO demonstrating clinically significant reductions in pain and substantial reductions in tumor volume and T2 hyperintensity with nirogacestat treatment – – Completed enrollment of Phase 2 trial evaluating nirogacestat in patients with ovarian granulosa cell tumors – – Highlighted encouraging Phase 1 and 2 clinical data from emerging pipeline programs at AACR and EHA – STAMFORD, Conn., Aug. 02, 2023 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (